Head to head
Vertex Pharmaceuticals vs Moderna
Side-by-side on the measures that matter, with a plain-English read. Full detail: VRTX · MRNA
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
vs
MRNA
Moderna
196.48+4.81%
1-year price shape — +619% over the period
Quant Rating A · 100/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| VRTX | MRNA | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 505.64 | 196.48 |
| Change today | +0.66% | +4.81% |
| 1-year return | +23.2% | +618.7% |
| Market cap | $128.16B | $78.44B |
| 52-week range | 402.58 – 560.25 | 22.28 – 212.22 |
| Valuation | ||
| P/E (TTM) | 29.45 | -24.62 |
| P/E percentile, own 5-yr range | 74th | 0th |
| P/B | 6.33 | 11.60 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 15.32 | -7.26 |
| Net profit (TTM) | $3.88B | $-2.90B |
| Revenue (TTM) | $12.59B | $2.21B |
| Revenue growth (YoY) | +12.5% | +4.4% |
| Gross margin | 86.0% | 22.8% |
| Operating margin | 37.9% | -150.2% |
| Net margin | 35.0% | -142.6% |
| Free cash flow (TTM) | $3.80B | $-1.24B |
| Ownership & sentiment | ||
| Institutional ownership | 97.2% | 80.5% |
| Insider activity (12mo) | 25 buy / 25 sell | 22 buy / 27 sell |
| Short interest (% of float) | 1.9% | 8.2% |
| Analyst consensus | 88% buy / 8% hold / 4% sell (24) | 23% buy / 62% hold / 15% sell (13) |
| Analyst price target | $580 (+15%) | $117 (-40%) |
| StockVane view | ||
| StockVane Quant Rating | C (67) | A (100) |
| Company | ||
| Employees | 6,400 | 4,700 |
| Founded | 1989 | 2010 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.